" class="no-js "lang="en-US"> Janux Appoints Zachariah McIver VP, Clinical Development
Tuesday, April 23, 2024

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah McIver as Vice President, Clinical Development. An accomplished physician-scientist with more than 15 years of experience in clinical research, Dr. McIver joins Janux after serving as Amgen’s Executive Medical Director, where he led cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies.

“Zach has extensive clinical research experience including leading the clinical development to maximize the value of bispecific T-cell engager assets across multiple hematologic and solid tumor malignancies,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “At Janux, Zach will play a key role in clinical development oversight as we advance our novel immunotherapy programs through clinical trials.”

“We’re excited to have Zach join the team as his experience with advanced T-cell engager programs will be especially important as we continue to advance our drug candidates in clinical trials,” said Wayne Godfrey, M.D., Chief Medical Officer at Janux.

“With TRACTr and TRACIr, Janux has built two very powerful platforms designed to overcome the toxicity and efficacy limitations of earlier generations of bispecific immunotherapies,” said Dr. Zachariah McIver. “I look forward to working with the team at Janux to advance the Company’s deep portfolio of next-generation bispecific immunotherapies to improve cancer treatment and help more patients.”

A board-certified hematologist and physician-scientist, Dr. McIver began his career specializing in hematological malignancies and immunotherapy working as a principal investigator at the Hematology Branch of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institute of Health (NIH). He played a key role in developing novel small molecules targeting alloreactive T-cells to prevent graft-versus-host-disease (GVHD) and established a stem cell transplant program for racial minority populations at the Wake Forest University School of Medicine. Dr. McIver also served as an attending physician at Wake Forest in the hematology/oncology department. Prior to this, he was an attending physician and a research investigator in the department of hematology/oncology at Tulane University School of Medicine.

Dr. McIver earned a B.S. in Physics and General Sciences from the University of Oregon, a Doctor of Osteopathic Medicine (D.O.) from Ohio University College of Osteopathic Medicine and a Ph.D. in Molecular Medicine and Translational Sciences at the Wake Forest University School of Medicine. He completed his internal medicine residency at the Cleveland Clinic, and his clinical fellowship in hematology and oncology at the NHLBI at the NIH. In addition, Dr. McIver is an active member of professional societies such as the American Society of Clinical Oncology, American Society of Hematology, and American College of Physicians.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more